RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of RO5126766 at different doses to find out
what effects, if any, it has on people with advanced lung cancer who have previously received
treatment with a PD-1 or PD-L1 inhibitor.